Principles for designing future regimens for multidrug-resistant tuberculosis. - Wikidata - awgldk - TriplyDB

Principles for designing future regimens for multidrug-resistant tuberculosis.

Principles for designing future regimens for multidrug-resistant tuberculosis.

http://www.wikidata.org/entity/Q37398037

about

Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis Multidrug-Resistant TB: Implementing the Right to Health through the Right to Enjoy the Benefits of Scientific Progress.Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.The need to accelerate access to new drugs for multidrug-resistant tuberculosis.Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment The scourge of tuberculosis and anti-tuberculosis drug resistance in Eastern Europe Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.Tuberculosis therapy in Mumbai: Critical importance of drug-susceptibility testing.Falling Short of the Rights to Health and Scientific Progress: Inadequate TB Drug Research and Access.A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB.Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.News on therapeutic management of MDR-tuberculosis: a literature review.Estimated generic prices for novel treatments for drug-resistant tuberculosis.Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa.Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting.Target regimen profiles for treatment of tuberculosis: a WHO document.New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.A Bayesian response-adaptive trial in tuberculosis: The endTB trial.Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.Tuberculosis

P2860

Q26765394-1D064043-EDFD-45E7-A838-30BABF5B8271 Q27003210-EEAB8805-D00C-4B4D-9B1F-211C71211C94 Q28544800-EE7EBFA3-BD7C-40D7-8F69-4725DDA9BD63 Q28554607-E5D735C5-6B23-43B1-BF82-5A2B01D30845 Q30380955-122485BA-975B-4B88-A48F-912BEF83130B Q33164956-5D4C5722-061B-42DE-A5BD-F8F1711B520B Q35815071-EF8A305C-AF1A-4366-9CFB-50E5DB32E8EE Q35933528-89E89585-2036-47C8-83D0-12EEC7730826 Q35960910-B826014D-2522-48D9-B4A4-907D8542C218 Q35990625-0D653B6C-7554-4558-BBD9-CDCA7A2B6E01 Q36386227-167D064A-9946-4726-A255-9A95F4DDC7FF Q36617024-09AE36A1-58FC-4436-8CFA-2A44AA4B572D Q36872176-2AC0AA3E-BDC2-4AFD-A34D-6D6351A9DD55 Q37351057-47DE14C1-B7BC-40B9-A3F4-F3D3B7E82A4D Q38582633-DE585428-7F7C-4F3D-AAD9-14A5C28429EE Q39014202-2556BFE1-E5CB-4C95-99F7-BDD78B389559 Q39398924-10708C7D-1E6C-4782-ABAB-444C9971AB58 Q40377338-0FAA80C2-AC6B-40AD-A0DC-D3FD4AC75EED Q40934368-D13DEF53-8F1E-47AE-9DD8-A56096009698 Q45922051-AF3095EB-E6DD-44D5-94AE-08BC2846C0B9 Q46813086-E15EA493-34A2-453A-9002-98596CF08788 Q47594312-6A03AD6D-BBCE-4B6B-914E-6E9754758CBE Q50170378-745668FE-4C28-4D4A-B010-F650000A184D Q55091455-E99E4EA5-02DD-40DD-9558-1E09B41801DE Q59200569-8FFA837B-B120-40B4-9B41-D31B43F5DB82

P2860

Principles for designing future regimens for multidrug-resistant tuberculosis.

http://www.wikidata.org/entity/Q37398037

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Principles for designing future regimens for multidrug-resistant tuberculosis.

@en

Principles for designing future regimens for multidrug-resistant tuberculosis.

@nl

type

label

Principles for designing future regimens for multidrug-resistant tuberculosis.

@en

Principles for designing future regimens for multidrug-resistant tuberculosis.

@nl

prefLabel

Principles for designing future regimens for multidrug-resistant tuberculosis.

@en

Principles for designing future regimens for multidrug-resistant tuberculosis.

@nl

P1433

Q37398037-7AF89CAD-282B-4B6D-8D92-21EA3DE5D909

P1476

Q37398037-B9AD728E-D47B-4A37-84A3-A95810C3E9D4

P2093

Q37398037-0EB73249-3966-47AC-A002-E74929D64D45

Q37398037-756F4293-3E17-41EF-8542-B95AD0C28FB7

Q37398037-8670ACD2-5BE8-443B-BE7A-8276C35678F7

Q37398037-B901300E-AAA5-4EB0-83EA-D6A657BC5B50

Q37398037-C9A000BA-6DCF-450E-86A1-77E0EA55DBAC

Q37398037-D48EF8CD-0B13-406A-A0F3-72D42A5E4DBB

Q37398037-E13F259F-B9BC-4B2E-87A3-64D05689315C

Q37398037-E1749775-9F50-471D-9878-A195AC6BF273

P2860

Q37398037-047FDC12-7CD2-43E2-A641-80DADF20F41A

Q37398037-09DC887E-9C4A-4E04-87EE-36CFA7697F22

Q37398037-13B8E916-EDC4-4C26-A39D-1D9734933CF0

Q37398037-14A1EA4E-54E6-49FA-B501-1810340C4D0C

Q37398037-22E2A14A-DB4A-4B48-95C9-F5ED9150E963

Q37398037-3350B259-FFEF-4DDF-BC64-767D78D7E3BB

Q37398037-52D78C5A-D661-486F-89B9-7FB7ADBBA09E

Q37398037-598F5905-B178-4A0D-A239-1B200048D026

Q37398037-6762C0BB-6FA5-45A1-8ADF-6B50219EAD0F

Q37398037-7B8A78F2-18D4-4A37-A4E5-7D5DAE042DD3

P304

Q37398037-24043F4D-8419-4433-8230-BCBD8C7DE2C5

P31

Q37398037-A0719BA7-7C9A-406E-ACAE-EE266E63FA5D

P356

Q37398037-7D3DCA63-C519-42EB-A437-3301269E4FEF

P407

Q37398037-7675CB85-F884-4E53-B00F-130BC78B5983

P433

Q37398037-2FB3FF94-3E4C-4169-9F2C-605685B9D67A

P478

Q37398037-A44950EA-B914-4047-9CDD-53956330D522

P50

Q37398037-3CA76F1D-5C05-40B3-8C78-49D0D2FF14B5

Q37398037-4AC14EAD-C5D0-4199-8789-DA4FF5478166

Q37398037-8A0ACEBD-3D47-46A2-962C-EDFE9399A053

Q37398037-E258C262-D45D-4D81-8DD2-E88AEC7AB4B0

P577

Q37398037-D963B7A6-558B-4D41-8225-79604EDB1B4B

P5875

Q37398037-48032FDB-0C60-4F03-AEA0-B0EB5BA75BC0

P698

Q37398037-7DFA2E6E-865A-4593-9D77-254127D65690

P921

Q37398037-6CC586DE-3F10-4448-9C15-8D1CD278B227

Q37398037-C9770147-8756-4EC6-81F3-A6AB3BE68517

P932

Q37398037-1494DF47-1CB2-4B8E-AA9E-957A565E8FB2

P356

P1433

Bulletin of the World Health Organization

P1476

Principles for designing future regimens for multidrug-resistant tuberculosis

@en

P2093

Bern-Thomas Nyang'wa

http://www.w3.org/2001/XMLSchema#string

Carole D Mitnick

http://www.w3.org/2001/XMLSchema#string

Eric Nuermberger

http://www.w3.org/2001/XMLSchema#string

Francis Varaine

http://www.w3.org/2001/XMLSchema#string

Grania Brigden

http://www.w3.org/2001/XMLSchema#string

Manica Balasegaram

http://www.w3.org/2001/XMLSchema#string

Michael Rich

http://www.w3.org/2001/XMLSchema#string

Philipp du Cros

http://www.w3.org/2001/XMLSchema#string

P2860

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

Delamanid for multidrug-resistant pulmonary tuberculosis

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up

Regimens of less than six months for treating tuberculosis.

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

P304

68-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2471/BLT.13.122028

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Phillips

Helen McIlleron

Jennifer Hughes

P577

2013-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259588743

http://www.w3.org/2001/XMLSchema#string

P698

24391302

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multiple drug resistance

P932

3865549

http://www.w3.org/2001/XMLSchema#string